Table 1. Associations of clinicopathological features with MTAP immunoexpression and gene status in primary myxofibrosarcomas.
MTAP Expression (n=87) | p-value | MTAP Gene (n=79) | p-value | |||
---|---|---|---|---|---|---|
Deficient | Positive | HD | Non-HD | |||
Sex | 1.000 | 0.936 | ||||
Male | 18 | 31 | 8 | 23 | ||
Female | 14 | 24 | 12 | 36 | ||
Age | 1.000 | 0.854 | ||||
<60 years | 12 | 21 | 23 | 7 | ||
≥60 years | 20 | 30 | 37 | 13 | ||
Location | 0.799 | 0.908 | ||||
Extremity | 23 | 42 | 15 | 45 | ||
Axial | 9 | 13 | 5 | 14 | ||
Tumor necrosis | 0.483 | 0.115 | ||||
<10% | 19 | 38 | 41 | 10 | ||
>=10% | 13 | 17 | 18 | 10 | ||
FNCLCC grade | 0.534 | 0.006* | ||||
grade 1 | 13 | 25 | 30 | 4 | ||
grade 2 | 12 | 23 | 24 | 9 | ||
grade 3 | 7 | 7 | 5 | 7 | ||
AJCC stage | 0.763 | 0.097 | ||||
Stage 1 | 6 | 14 | 16 | 1 | ||
Stage 2 | 12 | 19 | 21 | 9 | ||
Stage 3 | 13 | 20 | 20 | 10 | ||
Tumor size& | 7.314±6.528 | 6.347±3.701 | 0.633 | 6.600 4.808 | 7.311 5.551 | 0.612 |
Mitotic rate& | 12.81±13.143 | 10.33±1.695 | 0.585 | 8.780±9.180 | 19.050±15.408 | 0.011* |
MTAP gene status | <0.001 | |||||
Aberration (HD, PM) | 26 (16,10) | 4 (4,0) | ||||
No aberration (no HD or PM detected) | 3 | 46 |
HD: homozygous deletion, PM: promoter methylation,
:Statistically significant,
:t-test,